Tandem Diabetes Care (TNDM) EBT Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) EBT Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -2.47% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 7.77% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 5.75% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 37.81% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 4.82% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 61.06% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 32.11% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.57% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | 45.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.60% |
| Dec 31, 2025 | 31.86% |
| Sep 30, 2025 | 19.02% |
| Jun 30, 2025 | -64.57% |
| Mar 31, 2025 | -95.11% |
| Dec 31, 2024 | -88.70% |
| Sep 30, 2024 | -80.69% |
| Jun 30, 2024 | -109.95% |
| Mar 31, 2024 | -96.62% |
| Dec 31, 2023 | -56.59% |
| Sep 30, 2023 | -48.58% |
| Jun 30, 2023 | -5.82% |
| Mar 31, 2023 | -103.03% |
| Dec 31, 2022 | -99.32% |
| Sep 30, 2022 | -155.80% |
| Jun 30, 2022 | -104.60% |
| Mar 31, 2022 | 10.58% |
| Dec 31, 2021 | 43.73% |
| Sep 30, 2021 | 29.45% |
| Jun 30, 2021 | 30.91% |